# Trial to Determine the Efficacy/Safety of Plitidepsin vs Control in Patients With Moderate COVID-19 Infection

> **NCT04784559** · PHASE3 · TERMINATED · sponsor: **PharmaMar** · enrollment: 205 (actual)

## Conditions studied

- COVID-19 Infection

## Interventions

- **DRUG:** Plitidepsin
- **DRUG:** Dexamethasone
- **DRUG:** Remdesivir
- **DRUG:** Favipiravir

## Key facts

- **NCT ID:** NCT04784559
- **Lead sponsor:** PharmaMar
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-06-04
- **Primary completion:** 2023-03-01
- **Final completion:** 2023-03-01
- **Target enrollment:** 205 (ACTUAL)
- **Why stopped:** Sponsor has decided to end the study prematurely based on significant difficulties in the recruitment of patients, despite the implementation of corrective measures that still failed to increase the accrual rate required for a feasible completion.
- **Last updated:** 2025-02-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04784559

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04784559, "Trial to Determine the Efficacy/Safety of Plitidepsin vs Control in Patients With Moderate COVID-19 Infection". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT04784559. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*